Appili Therapeutics Inc.

APLI.TOTSXHealthcare● Active

$0.02

+$0.00(+0.00%)

Market Cap$1925490

P/E Ratio—

52W High$0.04

52W Low$0.01

Avg Volume52K

Open$0.02

Beta-0.23

Free Cash Flow Financials Revenue

Appili Therapeutics Inc. (APLI.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

APLI.TO · free cash flow · updated Jun 9, 2026

Core FCF metrics

APLI.TO · FCF · TTM · margin & CAGR

Free cash flow was $866,456 for FY2025 (fiscal year ending 2025-03-31), up 134.7% year-over-year The FCF margin was 862.6%.

FY2025 Free Cash Flow$866,456▲ +134.7% YoY

Trailing 12M (TTM)−$24,567Trailing 4Q sum · TTM negative vs latest FY positive

FCF Margin862.6%$866,456 ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

APLI.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$868,816(0M)$866,456▲ +134.7%862.6%

FY2024−$2.5M(0M)−$2.5M▲ +75.3%-301.4%

FY2023−$10.1M(0M)−$10.1M▲ +47.1%—

FY2022−$19.1M(0M)−$19.1M▼ 66.5%—

FY2021−$11.5M(0M)−$11.5M▼ 168.9%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

APLI.TO · P/FCF · FCF yield · FCF per share

Appili Therapeutics Inc. (APLI.TO) valuation ratios are currently unavailable — market cap, share count, or TTM data could not be retrieved from our data provider.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

Valuation ratios are unavailable — market cap, share count, or TTM data could not be retrieved. Individual metrics are shown where available.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-03-31

Cash flow statement summary

APLI.TO · cash flow statement · operating / investing / financing

For FY2025, Appili Therapeutics Inc. generated $0.9M in operating cash flow and spent 0M in capital expenditures, yielding $0.9M in free cash flow.

Operating Activities

+$0.9M

Cash from core business operations

2025-03-31

Investing Activities

−$0.0M

CapEx, acquisitions & investments

2025-03-31

Financing Activities

+$0.2M

Buybacks, dividends & debt

2025-03-31

FCF FormulaOperating CF ($0.9M) − |CapEx| (0M) = FCF ($0.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

APLI.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Appili Therapeutics Inc.YOU

APLI.TO

$866,456+134.7%862.6%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Appili Therapeutics Inc. (APLI.TO) reported free cash flow of $866,456 for FY2025 (fiscal year ending 2025-03-31), up 134.7% year-over-year. The FCF margin was 862.6%.

Based on available data, Appili Therapeutics Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $866,456 in FY2025.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

APLI.TO free cash flow · 8 questions

Appili Therapeutics Inc. free cash flow was $866,456 for FY2025, up 134.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$24,567.

APLI.TO free cash flowAPLI.TO FCFAPLI.TO FCF 2025APLI.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Appili Therapeutics Inc. · Appili Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026